Lower expression of HOXA9, accompanied by hypermethylation of its promoter region, was diagnostic or prognostic biomarker in tumors such as non-small cell lung cancer, ovarian cancer, and head and neck squamous cell carcinoma (48–50). This evidence concerns the gene HOXA9 and ovarian cancer.